利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.009 秒)

    SYSTEMS, DEVICES AND METHODS FOR ANTI-TL1A THERAPY
    2.
    发明公开
    SYSTEMS, DEVICES AND METHODS FOR ANTI-TL1A THERAPY 审中-公开
    SYSTEME，VORRICHTUNGEN UND VERFAHRENFÜRANTI-TL1A-THERAPIE

    公开(公告)号：EP3041580A1

    公开(公告)日：2016-07-13

    申请号：EP14842590.3

    申请日：2014-09-05

    申请人： Cedars-Sinai Medical Center

    发明人： TARGAN, Stephan R. ,  GONSKY, Rebecca ,  DEEM, Richard

    IPC分类号： A61P37/06

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/6863 ,  G01N2333/7151 ,  G01N2800/52

    摘要： The present invention relates to biomarker genes for diagnosing and treating diseases. Provided herein are systems and methods of diagnosing a disease in a patient based on the patient's expression levels of biomarker genes. Examples of the TL1A-associated disease include, but are not limited to, an inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), and fibrosis. Also provided herein are systems and methods of identifying a patient likely to be responsive to an anti-TL1A therapy, prescribing and/or administrating an anti-TL1A therapy to the patient based on the patient's expression levels of biomarker genes.

    摘要翻译： 本发明涉及用于诊断和治疗疾病的生物标记基因。 本文提供了基于患者的生物标记基因的表达水平来诊断患者疾病的系统和方法。 TL1A相关疾病的实例包括但不限于炎性肠病（IBD），克罗恩病（CD），溃疡性结肠炎（UC）和纤维化。 本文还提供了鉴定可能对抗TL1A治疗有反应的患者的系统和方法，根据患者的生物标记基因的表达水平开发和/或给予患者抗TL1A治疗。

    ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE
    3.
    发明公开
    ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE 有权
    IFNG甲基化炎症性肠疾病中的作用

    公开(公告)号：EP2689034A2

    公开(公告)日：2014-01-29

    申请号：EP12764214.8

    申请日：2012-03-26

    申请人： Cedars-Sinai Medical Center

    发明人： GONSKY, Rebecca ,  DEEM, Richard ,  TARGAN, Stephan R.

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158

    摘要： The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis.